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Further studies that are in progress are also brieﬂy outlined
to indicate the potential of developing these compounds into
biopharmaceuticals.
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ment Schemes (EQAS) of Microbiology laboratories in 2007
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Sabourian, S. Hekmat Yazdi
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Objective: The aim of this study was to determine ability
of Iranian microbiology laboratories for identiﬁcation and
susceptibility testing of two unknown microorganisms.
Methods: In Feb 2007 21th run of proﬁciency test-
ing of Iranian microbiology laboratories carried out by
Iranian health reference laboratories. In this survey two
unknown microorganisms including Salmonella Paratyphi
B and Staphylococcus aureus were submitted to 1305
microbiology laboratories. We asked all laboratories to
identify each microorganism and performance of suscepti-
bility testing just for S. paratyphi B against tetracycline,
nalidixic acid, ciproﬂoxacin, ampicillin and trimethoprim-
sulfamethoxazole. Scoring of results performed according to
WHO criteria. The maximum score of point for identiﬁcation
of each bacterium was 3 score and 5 score for suscepti-
bility testing (each antibiotic one score). The results were
analyzed by SPSS.
Results: Of 1305 laboratories only 1122 (.86%) laborato-
ries participated in our survey and 183 (14%) laboratories
did not participated in this study. Of 1122 laboratories,
523 (46.6%) laboratories identiﬁed S. paratyphi B cor-
rectly and obtained maximum 3 score of points and 488
(43.5%) laboratories partially identiﬁed this microorgan-
ism (1—2.5 score) and 111 (9.9%) laboratories misidentiﬁed
this microorganism. The mean score was 2.6. The results
of susceptibility testing of S. paratyphi B were relatively
satisﬁed for nalidixic acid, ciproﬂoxacin and trimethoprim-
sulfamethoxazole. However the results of susceptibility
testing for tetracycline and ampicillin were unsatisﬁed and
only the results of 578 (52.5%) of 1122 were correct for tetra-
cycline and 558 (49.7%) of laboratories reported correct
answer for ampicillin. The mean of score for susceptibility
testing was 3.88. Regarding to identiﬁcation Staphyloco-
cus aureus of 1122 laboratories 767 (68.4%) identiﬁed this
organism correctly and obtained maximum three score,
211 (18.8%) laboratories reported partially correct answer
(1—2.5 score) and 114 (12.8%) laboratories could not iden-
tiﬁed S.aureus. in total mean score for identiﬁcation of this
microorganism was 2.3.
Conclusions: This study revealed that the majority of
microbiology laboratories were able for identiﬁcation of S.
parathyphi B and S. aureus. Nearly 50% of laboratories pro-
duced incorrect susceptibility testing answer according to S.
paratyphi B for tetracycline and ampicillin.
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Multicenter Evaluation of Tigecycline Activity in India:
Report from the SENTRY Antimicrobial Surveillance Pro-
gram (2006)
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Background: Tigecycline, the initial representative of
the glycylcyclines, presents a therapy option for emerging
multidrug-resistant (MDR) pathogens. India, a nation rarely
monitored in global surveillance programs, appears in need
of agents active against MDR isolates of Enterobacteriaceae
(ESBLs), Acinetobacters (carbapenem-resistant) and Gram-
positive cocci (MRSA, VRE). Numerous sites were sampled
using reference susceptibility methods.
Methods: Eleven sites forwarded 1,714 strains to a
regional monitor (WCH, Adelaide, Australia) that sus-
ceptibility tested 27 antimicrobials by CLSI methods
(M7-A7, 2006). Identiﬁcations were conﬁrmed and inter-
pretive/screening criteria were also by CLSI guidelines
(M100-S18, 2008), except for tigecycline where United
States - Food and Drug Administration breakpoints were
applied. Major pathogens were: S. aureus (250), coagulase-
negative staphylococci (CoNS; 228), enterococci (93),
Enterobacters (76), E. coli (217), K. pneumoniae (268),
Salmonella spp. (55) and Acinetobacters (108).
Results: Tigecycline was active against 98—100% of indi-
cated/tabulated species, lowest for Acinetobacter spp.
S. aureus tigecycline MIC90 values were not inﬂuenced
by oxacillin susceptibility patterns (0.25mg/L; 100% S).
Increased resistance patterns noted were: tetracycline-
resistant (4—100%; average 53%), AmpC, ESBL- and
ﬂuoroquinolone resistance in Enterobacteriaceae (8—70,
14—78, 1—91%, respectively), VRE (1%), MRSA (36%) and
Acinetobacters carbapenem-resistant (38%). S. typhi and S.
paratyphi were common (tigecycline MIC90, 0.5mg/L), and
84% were nalidixic acid-resistant. Carbapenem resistance in
Enterobacteriaceae (1—7%) was consistent with harbouring
metallo--lactamases; conﬁrmed by PCR testing.
Conclusions: Although MDR rates across Gram-positive
and -negative species (particularly among enteric bacilli
and Acinetobacters) was high in India, tigecycline remained
active (MIC90, 1mg/L overall) against these MDR strains.
Tigecycline exhibited promising spectrum/potency exceed-
ing currently available agents against sampled isolates from
India.
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